SAB Biotherapeutics, Inc. (SABSW)
- Previous Close
0.0234 - Open
0.0220 - Bid --
- Ask --
- Day's Range
0.0220 - 0.0220 - 52 Week Range
0.0220 - 0.0220 - Volume
1,988 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) 0.70
- PE Ratio (TTM)
0.08 - EPS (TTM)
0.2920 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
www.sabbiotherapeutics.comRecent News: SABSW
View MoreCompare To: SABSW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SABSW
View MoreValuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-58.80%
Return on Equity (ttm)
-122.49%
Revenue (ttm)
2.78M
Net Income Avi to Common (ttm)
-40.32M
Diluted EPS (ttm)
0.2920
Balance Sheet and Cash Flow
Total Cash (mrq)
37.33M
Total Debt/Equity (mrq)
11.58%
Levered Free Cash Flow (ttm)
-26.69M
Company Insights: SABSW
SABSW does not have Company Insights